Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Allergan PLC (NYSE:AGN)

Paying users zone. Data is hidden behind: .

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey
Unlock

This is a one-time payment. There is no automatic renewal.

Cash Flow Statement
Quarterly Data

Beginner level

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company’s balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Allergan PLC, consolidated cash flow statement (quarterly data)

US$ in thousands

Microsoft Excel LibreOffice Calc
3 months ended: Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Net income (loss)
Depreciation
Amortization
Provision for inventory reserve
Share-based compensation
Deferred income tax benefit
Pre-tax gain sale of generics business
Non-cash tax effect of gain on sale of generics business
Goodwill impairments
In-process research and development impairments
(Gain) loss on asset sales and impairments, net
Net income impact of other-than-temporary loss on investment in Teva securities
(Gain) loss on sale of Teva securities, net
Charge to settle Teva related matters
Loss on forward sale of Teva shares
Amortization of inventory step-up
Gain on sale of businesses
Non-cash extinguishment of debt
Cash charge related to extinguishment of debt
Amortization of deferred financing costs
Non-cash lease expense
Contingent consideration adjustments, including accretion
Excess tax benefit from stock-based compensation
Other, net
(Increase) decrease in accounts receivable, net
(Increase) decrease in inventories
(Increase) decrease in prepaid expenses and other current assets
Increase (decrease) in accounts payable and accrued expenses
Increase (decrease) in income and other net taxes payable
Increase (decrease) in other assets and liabilities
Changes in assets and liabilities, net of effects of acquisitions
Reconciliation to net cash provided by operating activities
Net cash provided by operating activities
Additions to property, plant and equipment
Additions to product rights and other intangibles
Sale of generics business
Additions to investments
Proceeds from sale of investments and other assets
Payments to settle Teva related matters
Proceeds from sales of property, plant and equipment
Acquisitions of businesses, net of cash acquired
Net cash (used in) provided by investing activities
Proceeds from borrowings of long-term indebtedness, including credit facility
Payments on debt, including finance lease obligations and credit facility
Cash charge related to extinguishment of debt
Payments of contingent consideration and other financing
Proceeds from stock plans
Proceeds from forward sale of Teva securities
Payments to settle Teva related matters
Debt issuance and other financing costs
Proceeds from issuance of preferred shares
Proceeds from issuance of ordinary shares
Repurchase of ordinary shares
Dividends paid
Excess tax benefit from stock-based compensation
Net cash provided by (used in) financing activities
Effect of currency exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents

Based on: 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-18), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-08), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-15), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-09), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-24), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-06), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-11).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Allergan PLC’s net cash provided by operating activities decreased from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Allergan PLC’s net cash (used in) provided by investing activities increased from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Allergan PLC’s net cash provided by (used in) financing activities increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.